Zacks Investment Research upgraded shares of Glaukos Corporation (NYSE:GKOS) from a sell rating to a hold rating in a report released on Monday morning.

According to Zacks, “Glaukos Corporation is an ophthalmic medical technology company. The Company develops, manufactures and markets medical devices for the treatment of glaucoma. Its product pipeline consists of iStent Inject, the iStent Supra and iDose. The company operates primarily in United States, Germany, Europe, the Asia Pacific, Canada and internationally. Glaukos Corporation is headquartered in Laguna Hills, California. “

A number of other equities analysts have also recently commented on the stock. Stifel Nicolaus reiterated a buy rating on shares of Glaukos Corporation in a research report on Thursday, September 14th. Piper Jaffray Companies reiterated a buy rating and issued a $38.00 target price on shares of Glaukos Corporation in a research report on Friday, September 15th. BidaskClub upgraded shares of Glaukos Corporation from a sell rating to a hold rating in a research report on Friday, September 1st. BMO Capital Markets reiterated a buy rating and issued a $54.00 target price on shares of Glaukos Corporation in a research report on Friday, September 1st. Finally, Cantor Fitzgerald reiterated a buy rating and issued a $60.00 target price (up previously from $54.00) on shares of Glaukos Corporation in a research report on Thursday, September 14th. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of Buy and a consensus target price of $46.86.

Glaukos Corporation (NYSE GKOS) traded down $0.09 during trading on Monday, hitting $30.00. 662,000 shares of the stock traded hands, compared to its average volume of 619,753. The stock has a market cap of $1,040.07, a PE ratio of 250.75 and a beta of 1.25. Glaukos Corporation has a 12-month low of $28.74 and a 12-month high of $52.49.

Glaukos Corporation (NYSE:GKOS) last posted its quarterly earnings data on Tuesday, November 7th. The medical instruments supplier reported $0.04 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.02) by $0.06. The firm had revenue of $40.41 million for the quarter, compared to analysts’ expectations of $38.69 million. Glaukos Corporation had a negative net margin of 0.64% and a positive return on equity of 3.50%. The business’s quarterly revenue was up 36.6% on a year-over-year basis. During the same quarter last year, the company posted $0.03 EPS. equities research analysts forecast that Glaukos Corporation will post -0.02 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Glaukos Corporation (GKOS) Upgraded to “Hold” at Zacks Investment Research” was originally published by Daily Political and is the property of of Daily Political. If you are reading this news story on another site, it was stolen and republished in violation of US and international copyright & trademark laws. The correct version of this news story can be viewed at https://www.dailypolitical.com/2017/11/14/glaukos-corporation-gkos-upgraded-to-hold-at-zacks-investment-research.html.

In other news, CEO Thomas William Burns sold 73,788 shares of Glaukos Corporation stock in a transaction dated Thursday, September 7th. The shares were sold at an average price of $41.36, for a total transaction of $3,051,871.68. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Orbimed Advisors Llc sold 580,200 shares of Glaukos Corporation stock in a transaction dated Tuesday, September 5th. The shares were sold at an average price of $38.73, for a total transaction of $22,471,146.00. The disclosure for this sale can be found here. In the last three months, insiders sold 980,200 shares of company stock worth $37,900,263. Insiders own 16.40% of the company’s stock.

Institutional investors and hedge funds have recently made changes to their positions in the company. Ameritas Investment Partners Inc. boosted its stake in shares of Glaukos Corporation by 93.1% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,514 shares of the medical instruments supplier’s stock valued at $104,000 after purchasing an additional 1,212 shares in the last quarter. BNP Paribas Arbitrage SA boosted its stake in shares of Glaukos Corporation by 740.6% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 3,539 shares of the medical instruments supplier’s stock valued at $147,000 after purchasing an additional 3,118 shares in the last quarter. Prudential Financial Inc. bought a new stake in shares of Glaukos Corporation during the 1st quarter valued at about $204,000. Los Angeles Capital Management & Equity Research Inc. bought a new stake in shares of Glaukos Corporation during the 2nd quarter valued at about $262,000. Finally, UBS Asset Management Americas Inc. bought a new stake in shares of Glaukos Corporation during the 2nd quarter valued at about $274,000.

Glaukos Corporation Company Profile

Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm’s canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream.

Analyst Recommendations for Glaukos Corporation (NYSE:GKOS)

Receive News & Ratings for Glaukos Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos Corporation and related companies with MarketBeat.com's FREE daily email newsletter.